Related references
Note: Only part of the references are listed.Targeting HER2-positive breast cancer: advances and future directions
Sandra M. Swain et al.
NATURE REVIEWS DRUG DISCOVERY (2023)
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials
Aranzazu Fernandez-Martinez et al.
JAMA ONCOLOGY (2023)
Multi-omic machine learning predictor of breast cancer therapy response
Stephen-John Sammut et al.
NATURE (2022)
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Clinical Review on the Management of Hormone Receptor-Positive Metastatic Breast Cancer
Nicholas P. McAndrew et al.
JCO ONCOLOGY PRACTICE (2022)
Identification of the JNK-Active Triple-Negative Breast Cancer Cluster Associated With an Immunosuppressive Tumor Microenvironment
Takashi Semba et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update
Fabrice Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Breast tumor microenvironment structures are associated with genomic features and clinical outcome
Esther Danenberg et al.
NATURE GENETICS (2022)
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
J. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial
Sacha J. Howell et al.
LANCET ONCOLOGY (2022)
cGAS-STING drives the IL-6-dependent survival of chromosomally instable cancers
Christy Hong et al.
NATURE (2022)
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
Daniel Zingg et al.
NATURE (2022)
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
Hope S. Rugo et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1) a randomised, open-label, multicentre, phase 3 trial
Francois-Clement Bidard et al.
LANCET ONCOLOGY (2022)
Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+breast tumors
Elisa Rivas et al.
NATURE COMMUNICATIONS (2022)
Targeting CDK4 and CDK6 in cancer
Shom Goel et al.
NATURE REVIEWS CANCER (2022)
Multi-omic machine learning predictor of breast cancer therapy response
Stephen-John Sammut et al.
NATURE (2022)
Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer
Yuanyuan Zhang et al.
CANCER CELL (2021)
The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer
Theresa E. Hickey et al.
NATURE MEDICINE (2021)
A Population-Based Study of Genes Previously Implicated in Breast Cancer
Chunling Hu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
Kevin Kalinsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age
Martine Piccart et al.
LANCET ONCOLOGY (2021)
Spatial deconvolution of HER2-positive breast cancer delineates tumor-associated cell type interactions
Alma Andersson et al.
NATURE COMMUNICATIONS (2021)
A single-cell RNA expression atlas of normal, preneoplastic and tumorigenic states in the human breast
Bhupinder Pal et al.
EMBO JOURNAL (2021)
Breast tumours maintain a reservoir of subclonal diversity during expansion
Darlan C. Minussi et al.
NATURE (2021)
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer
Ayse Bassez et al.
NATURE MEDICINE (2021)
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Genomic profile of advanced breast cancer in circulating tumour DNA
Belinda Kingston et al.
NATURE COMMUNICATIONS (2021)
Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors
Roman Uzhachenko et al.
CELL REPORTS (2021)
A single-cell and spatially resolved atlas of human breast cancers
Sunny Z. Wu et al.
NATURE GENETICS (2021)
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Andrew N. J. Tutt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
RNF2 ablation reprograms the tumor-immune microenvironment and stimulates durable NK and CD4+ T-cell-dependent antitumor immunity
Zhuo Zhang et al.
NATURE CANCER (2021)
Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy
Jason I. Griffiths et al.
NATURE CANCER (2021)
STEM CELLS AND THE DIFFERENTIATION HIERARCHY IN MAMMARY GLAND DEVELOPMENT
Nai Yang Fu et al.
PHYSIOLOGICAL REVIEWS (2020)
Pan-cancer analysis of whole genomes
Peter J. Campbell et al.
NATURE (2020)
The single-cell pathology landscape of breast cancer
Hartland W. Jackson et al.
NATURE (2020)
The evolutionary history of 2,658 cancers
Moritz Gerstung et al.
NATURE (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
HER2-Low Breast Cancer: Pathological and Clinical Landscape
Paolo Tarantino et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer
Yann Kieffer et al.
CANCER DISCOVERY (2020)
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
Sara M. Tolaney et al.
LANCET ONCOLOGY (2020)
Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases
Zheng Hu et al.
NATURE GENETICS (2020)
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Stephen R. D. Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A. Mittendorf et al.
LANCET (2020)
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
Leisha A Emens et al.
LANCET ONCOLOGY (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Harold J. Burstein
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4+ and PDPN+ CAFs to clinical outcome
Gil Friedman et al.
NATURE CANCER (2020)
The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism
Gerta Hoxhaj et al.
NATURE REVIEWS CANCER (2020)
Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer
H. Raza Ali et al.
NATURE CANCER (2020)
Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets
Luca Cassetta et al.
CANCER CELL (2019)
Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers
Tina Gruosso et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups
Oscar M. Rueda et al.
NATURE (2019)
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER plus breast cancer
Luigi Formisano et al.
NATURE COMMUNICATIONS (2019)
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
Ana C. Garrido-Castro et al.
CANCER DISCOVERY (2019)
A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer
Johanna Wagner et al.
CELL (2019)
Genomic characterization of metastatic breast cancers
Francois Bertucci et al.
NATURE (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
Joseph A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies
Lindsay Angus et al.
NATURE GENETICS (2019)
Breast cancer
Nadia Harbeck et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
An innate-like Vδ1+ γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer
Yin Wu et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
Nasim Mavaddat et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2019)
Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
Y. Bareche et al.
ANNALS OF ONCOLOGY (2018)
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
Ana Costa et al.
CANCER CELL (2018)
Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing
Charissa Kim et al.
CELL (2018)
Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment
Elham Azizi et al.
CELL (2018)
Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing
Anna K. Casasent et al.
CELL (2018)
Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis
Peter Savas et al.
NATURE MEDICINE (2018)
Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer
Darren K. Patten et al.
NATURE MEDICINE (2018)
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
P. A. Francis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Pedram Razavi et al.
CANCER CELL (2018)
A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging
Leeat Keren et al.
CELL (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
Maki Tanioka et al.
CLINICAL CANCER RESEARCH (2018)
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Karoline B. Kuchenbaecker et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Association analysis identifies 65 new breast cancer risk loci
Kyriaki Michailidou et al.
NATURE (2017)
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
Jennifer L. Guerriero et al.
NATURE (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer
Woosung Chung et al.
NATURE COMMUNICATIONS (2017)
Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer
Juan M. Cejalvo et al.
CANCER RESEARCH (2017)
Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis
Josee-Lyne Ethier et al.
BREAST CANCER RESEARCH (2017)
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Sherene Loi et al.
CLINICAL CANCER RESEARCH (2016)
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Peter Savas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
The global decrease in cancer mortality: trends and disparities
D. Hashim et al.
ANNALS OF ONCOLOGY (2016)
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Serena Nik-Zainal et al.
NATURE (2016)
Punctuated copy number evolution and clonal stasis in triple-negative breast cancer
Ruli Gao et al.
NATURE GENETICS (2016)
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
F. Cardoso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes
Bernard Pereira et al.
NATURE COMMUNICATIONS (2016)
Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases
Katherine A. Hoadley et al.
PLOS MEDICINE (2016)
Hereditary breast and ovarian cancer: new genes in confined pathways
Finn Cilius Nielsen et al.
NATURE REVIEWS CANCER (2016)
The biology and function of fibroblasts in cancer
Raghu Kalluri
NATURE REVIEWS CANCER (2016)
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
Giovanni Ciriello et al.
CELL (2015)
Neutrophils support lung colonization of metastasis-initiating breast cancer cells
Stefanie K. Wculek et al.
NATURE (2015)
Progesterone receptor modulates ERα action in breast cancer
Hisham Mohammed et al.
NATURE (2015)
Subclonal diversification of primary breast cancer revealed by multiregion sequencing
Lucy R. Yates et al.
NATURE MEDICINE (2015)
ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer
Rinath Jeselsohn et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification
Charlotte K. Y. Ng et al.
GENOME BIOLOGY (2015)
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Dejan Juric et al.
NATURE (2015)
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
M. Piccart et al.
ANNALS OF ONCOLOGY (2014)
Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer
Aleix Prat et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Clonal evolution in breast cancer revealed by single nucleus genome sequencing
Yong Wang et al.
NATURE (2014)
Progesterone signalling in breast cancer: a neglected hormone coming into the limelight
Cathrin Brisken
NATURE REVIEWS CANCER (2013)
The Life History of 21 Breast Cancers
Serena Nik-Zainal et al.
CELL (2012)
The landscape of cancer genes and mutational processes in breast cancer
Philip J. Stephens et al.
NATURE (2012)
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Sohrab P. Shah et al.
NATURE (2012)
Whole-genome analysis informs breast cancer response to aromatase inhibition
Matthew J. Ellis et al.
NATURE (2012)
Sequence analysis of mutations and translocations across breast cancer subtypes
Shantanu Banerji et al.
NATURE (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Christina Curtis et al.
NATURE (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
Nicholas Turner et al.
CANCER RESEARCH (2010)
BRCA1 Basal-like Breast Cancers Originate from Luminal Epithelial Progenitors and Not from Basal Stem Cells
Gemma Molyneux et al.
CELL STEM CELL (2010)
Genome remodelling in a basal-like breast cancer metastasis and xenograft
Li Ding et al.
NATURE (2010)
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Aleix Prat et al.
BREAST CANCER RESEARCH (2010)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers
Elgene Lim et al.
NATURE MEDICINE (2009)
Histological and molecular types of breast cancer: is there a unifying taxonomy?
Britta Weigelt et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
HER2 status and benefit from adjuvant trastuzumab in breast cancer
Soonmyung Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors
Jason I. Herschkowitz et al.
GENOME BIOLOGY (2007)
Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis
R Mehra et al.
CANCER RESEARCH (2005)
Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors
G Danaei et al.
LANCET (2005)
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
R Rouzier et al.
CLINICAL CANCER RESEARCH (2005)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Towards an integrated model for breast cancer etiology - The lifelong interplay of genes, lifestyle, and hormones
SE Hankinson et al.
BREAST CANCER RESEARCH (2004)
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
DB Agus et al.
CANCER CELL (2002)
Gene expression profiling predicts clinical outcome of breast cancer
LJ van't Veer et al.
NATURE (2002)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)